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The physiological function of the epidermal growth factor receptor
(EGFR) is to regulate epithelial tissue development and homeostasis. In
pathological settings, mostly in lung and breast cancer and in glioblastoma,
the EGFR is a driver of tumorigenesis. Inappropriate activation of the
EGFR in cancer mainly results from amplification and point mutations at
the genomic locus, but transcriptional upregulation or ligand overproduc-
tion due to autocrine/paracrine mechanisms has also been described. More-
over, the EGFR is increasingly recognized as a biomarker of resistance in
tumors, as its amplification or secondary mutations have been found to
arise under drug pressure. This evidence, in addition to the prominent
function that this receptor plays in normal epithelia, has prompted intense
investigations into the role of the EGFR both at physiological and at
pathological level. Despite the large body of knowledge obtained over the
last two decades, previously unrecognized (herein defined as ‘noncanoni-
cal’) functions of the EGFR are currently emerging. Here, we will initially
review the canonical ligand-induced EGFR signaling pathway, with partic-
ular emphasis to its regulation by endocytosis and subversion in human
tumors. We will then focus on the most recent advances in uncovering non-
canonical EGFR functions in stress-induced trafficking, autophagy, and
energy metabolism, with a perspective on future therapeutic applications.
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1. Introduction
The epidermal growth factor receptor (EGFR) belongs
to the ErbB family of receptor tyrosine kinases
(RTKs) and exerts critical functions in epithelial cell
physiology (Schlessinger, 2014). It is frequently
mutated and/or overexpressed in different types of
human cancers and is the target of multiple cancer
therapies currently adopted in the clinical practice
(Yarden and Pines, 2012).
Early studies of the EGFR pathway started with the
discovery of EGF in 1963 by Stanley Cohen and, later
in the 1980s, of the EGFR gene. Since then, biochemi-
cal, structural, and genetic studies have depicted the
molecular mechanisms underlying receptor transphos-
phorylation, which usually occurs in response to ligand
stimulation, and the consequent activation of the intra-
cellular signaling cascade. This cascade consists in the
activation of multiple pathways that deliver the infor-
mation from the cell surface, and the intracellular
vesicular compartments, to the nucleus leading to the
activation of genes responsible for cell proliferation,
survival, and differentiation (Lemmon and Sch-
lessinger, 2010; Schlessinger, 2014).
The best characterized functions of the EGFR are
in the context of ligand- and kinase-dependent activa-
tion, that is, the ‘canonical’ EGFR signaling pathway
(Lemmon and Schlessinger, 2010). However, novel
functions, both kinase dependent and independent,
have been recently identified. They reveal unexpected
roles of the EGFR, such as in the regulation of autop-
hagy and metabolism (Tan et al., 2016a). These non-
canonical functions are generally induced by cellular
and environmental stresses. Several of these ‘stress
pathways’ are activated in cancer cells to provide them
with a survival advantage and resistance to therapy
(Jutten et al., 2013; Tan et al., 2016a). This has led to
an emerging concept that concomitant targeting of
EGFR and stress pathways might offer a window of
opportunity in cancer treatment.
2. Canonical ligand-dependent EGFR
signaling pathway
Under unstimulated conditions, the EGFR is mainly
found in an auto-inhibited, dimerization-incompetent,
state at the plasma membrane (PM). Ligand binding
promotes receptor dimerization, which determines a
series of structural rearrangements that are conveyed
to the cytoplasmic domain allowing the formation of
asymmetric dimers between the two juxtaposed cat-
alytic domains (Zhang et al., 2006; Fig. 1A). These
events lead to the allosteric activation of the EGFR
kinase and to the trans-autophosphorylation of critical
tyrosine residues in the cytoplasmic receptor tail,
thereby triggering the signaling cascade (Lemmon
et al., 2014). For in-depth molecular details of EGFR
activation, we refer the reader to recent reviews
(Kovacs et al., 2015; Lemmon et al., 2014).
Ligand-induced EGFR phosphorylation and confor-
mational changes occurring in the intracellular tail
lead also to the recruitment of the endocytic machin-
ery that mediates receptor endocytosis, with internal-
ization rates that are ~ 10-fold higher for ligand-
bound than for unliganded EGFR (Conte and Sigis-
mund, 2016).
The EGFR can heterodimerize with other ErbB
family members, ErbB2, ErbB3, and ErbB4 (Lemmon
et al., 2014), with critical effects on receptor trafficking
and signaling (Lenferink et al., 1998). Indeed, hetero-
dimers have a reduced ligand-binding strength, leading
to ligand dissociation in endosomes, and they are
unable to recruit Cbl and the endocytic machinery as
efficiently as EGFR homodimers (Baulida et al., 1996;
Lenferink et al., 1998; Levkowitz et al., 1998; Water-
man et al., 1999). Signaling from heterodimers is
therefore enhanced and predicted to be more onco-
genic than signaling from homodimers.
Seven EGFR ligands have been described to date,
which have been shown to induce specific cellular
responses and intracellular trafficking events both
in vitro and in vivo (Roepstorff et al., 2009; Wilson
et al., 2012; Yang et al., 2017). In some cases, these dif-
ferences are determined by the different strength of the
ligand–receptor interaction, which dictates whether the
ligand dissociates (as in the case of TGFa transforming
growth factor a) or not (as in the case of EGF) from the
receptor in the mild acidic pH of the endosomes, favor-
ing EGFR recycling or degradation, respectively. In
other instances, the different signaling properties of the
various ligands have been attributed to their ability to
differentially stabilize the EGFR dimers, therefore deter-
mining specific signaling outputs (Freed et al., 2017).
Once activated at the PM, the EGFR also under-
goes ubiquitination by the E3 ligase Cbl in complex
with the adaptor molecule Grb2 (Levkowitz et al.,
1998; Sigismund et al., 2013; Waterman et al., 2002).
EGFR ubiquitination is threshold controlled by EGF
concentration (Sigismund et al., 2013) and occurs on
several lysine residues within the kinase domain
(Huang et al., 2006). In specific cell contexts, EGFR
ubiquitination works as a signal for receptor internal-
ization into the nonclathrin endocytic (NCE) pathway.
At later stages of trafficking, ubiquitination becomes a
common requirement to target receptors to lysosomal
degradation (see Section 2.1).
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Fig. 1. Scheme of EGFR and its mutations in glioblastoma and in lung and colorectal cancer. (A) Schematic representation of the EGFR and
EGF-induced receptor activation. The EGFR extracellular region encompasses domains I, II, III, and IV; following are the transmembrane
region (TM), the intracellular juxtamembrane domain (iJM), the tyrosine kinase domain (TK), and the carboxyl-terminal tail (carboxy tail). EGF
binding to the receptor unmasks a dimerization motif and determines structural rearrangements that are conveyed to the cytoplasmic
domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. (B) Most frequent EGFR mutations in
glioblastoma, in NSCLC (non-small-cell lung cancer), and in CRC (colorectal cancer). Mutations found in tumors resistant to EGFR blockade
are shown in red. In CRC, the indicated EGFR mutations have been identified in patients that progressed upon cetuximab treatment (Arena
et al., 2015, 2016; Montagut et al., 2012; Van Emburgh et al., 2016).
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Ligand-dependent EGFR activation transduces mul-
tiple signaling pathways, including the Ras/MAPK
pathway, the PI3K/AKT pathway, and the phospholi-
pase C (PLC)/protein kinase C (PKC) signaling cas-
cade (Lemmon and Schlessinger, 2010). Canonical
EGFR signaling is critical for several cellular functions
including survival, proliferation, differentiation, and
motility.
The quality, the amplitude, and the duration of
these signaling events are tightly regulated by compart-
mentalization and trafficking of the EGFR along the
endocytic pathway, as discussed in the following para-
graphs.
2.1. Temporal regulation of EGFR signaling by
endocytosis
The first step in the regulation of EGFR signaling
takes place at the PM, where the EGFR is internalized
through multiple endocytic pathways with different
morphological, molecular, and kinetic features that
influence receptor activity and fate (Barbieri et al.,
2016; Bergeron et al., 2016). Both clathrin-mediated
endocytosis (CME) and several NCE pathways are
involved in EGFR internalization (Barbieri et al.,
2016). EGFR-CME is active at all ligand concentra-
tions in all type of cells (Carpentier et al., 1982; Goh
et al., 2010; Hanover et al., 1984; Jiang et al., 2003;
Sigismund et al., 2008; Sorkin and Carpenter, 1993).
Conversely, the EGFR-NCE pathways – despite their
molecular and morphological differences – are gener-
ally activated at higher, but still physiologically rele-
vant, EGF doses (≥ 10 ngmL1) and their significance
is cell context dependent (Boucrot et al., 2015; Caldieri
et al., 2017; Orth et al., 2006; also reviewed in Barbieri
et al., 2016).
The molecular mechanisms underlying CME are
well defined, with clathrin, adaptor protein 2 (AP2)
and the large GTPase dynamin being the major play-
ers (see Kirchhausen et al., 2014; McMahon and Bou-
crot, 2011 for recent reviews). CME controls EGFR
signaling through various mechanisms. At the PM,
clustering of EGFR in clathrin-coated pits (CCPs) is
required to optimize receptor phosphorylation, and to
amplify and spatially constrain EGFR signaling
(Garay et al., 2015; Ibach et al., 2015). AP2 exerts a
critical function during the assembly of CCPs and it is
essential to maintain the right vesicle size, with pre-
dictable consequences for receptor clustering and sig-
naling (Aguet et al., 2013; Kadlecova et al., 2017;
Miller et al., 2015). In addition to AP2, dynamin and
the cargo itself tightly regulate the timing of CCP
assembly allowing for receptor clustering and
productive signaling (Loerke et al., 2009). Some non-
small-cell lung cancer (NSCLC) cells show an
aberrantly accelerated CME, with deregulated CCP
initiation and maturation (Chen et al., 2017). This
phenotype has been linked to the activation of the
neuronal dynamin isoform, dynamin1 (dyn1), in non-
neuronal cells, and/or to the overexpression of the cla-
thrin light chain b (CLCb; Chen et al., 2017). The
increased uncontrolled CME rate causes increased
EGFR recycling and signaling through AKT, promot-
ing cancer cell survival (Chen et al., 2017). Interest-
ingly, both dyn1 and CLCb are upregulated in
NSCLC and breast cancer (reviewed in Schmid, 2017).
In instances in which NCE is activated in parallel to
CME, the integration of the two pathways is critical in
determining the final signaling response. For instance,
in HeLa and in other epithelial cells, CME and NCE
determine opposing receptor fates (Sigismund et al.,
2008): CME mainly induces receptor recycling (with
limited EGFR degradation), while NCE – which
requires EGFR ubiquitination as an internalization
signal (Sigismund et al., 2005, 2013) – targets the
majority of internalized EGFRs to degradation in the
lysosome. In this way, CME, which is active at low
EGF concentrations, directs the EGFR/EGF complex
away from degradation and toward recycling to main-
tain signaling when ligand is limited. In addition,
through recycling, CME also serves to prolong EGFR
signaling, a requirement critical to achieve a produc-
tive proliferative response, and to polarize EGFR sig-
naling to specific regions of the PM (Bisi et al., 2013;
Sigismund et al., 2012). Polarized trafficking of cargo
proteins to regions of the PM represents one of the
most frequently altered functions of endo/exocytosis in
cancer as it is primarily involved in migration and
invasion of metastatic cells and in maintenance of
epithelial cell polarity (reviewed in Lanzetti and Di
Fiore, 2017).
EGFR-NCE is activated only at high EGF concen-
trations and is critical for long-term attenuation of
EGFR signaling by directing EGFRs to lysosomal
degradation. Recently, the mechanism governing
EGFR-NCE has been elucidated. This endocytic route
depends on the function of an endoplasmic reticulum
(ER)-resident protein, reticulon 3 (RTN3), which is
involved in the formation of contact sites between the
ER and regions of the PM where EGFR-NCE occurs
(Caldieri et al., 2017, also discussed in Section 3.1).
This modality of EGFR-NCE appears to act as a safe-
guard against excessive EGFR signaling, and might
represent a mechanism for modulating EGFR signal-
ing at specific PM regions where polarized functions
take place, an issue that deserves further investigation.
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Other types of EGFR-NCE occur at specific PM loca-
tions and are connected with cell migration. They
include (a) the macropinocytic-like pathway that origi-
nates, in mouse and human fibroblasts, from actin-
based membrane ruffles, defined as circular or dorsal
ruffles (Orth et al., 2006), implicated in three-dimensional
cell motility and extracellular matrix degradation (Suet-
sugu et al., 2003), and (b) the fast endophilin-mediated
endocytosis (FEME). This latter pathway is involved in
the internalization of several G-protein-coupled recep-
tors and RTKs, including the EGFR, and is active at
the leading edge of migrating cells, suggesting its
involvement in polarized signaling during cell migration
(Boucrot et al., 2015).
Once internalized, EGFRs reach the early endo-
somes (EEs), a further ‘level’ in the regulation of
EGFR signaling. At this station, EGFRs are sorted
toward different fates, recycling or degradation (re-
viewed in Wandinger-Ness and Zerial, 2014). Receptor
recycling is usually the default pathway. Escape from
recycling is determined by EGFR ubiquitination,
which is an active signal recognized by the ESCRT
(endosomal sorting complexes required for transport)
complexes that, through a stepwise process, sort recep-
tors into multivesicular bodies (MVBs) and into lyso-
somes for degradation (reviewed in Raiborg and
Stenmark, 2009; Wollert et al., 2009).
Besides sorting, endosomes work as platforms for
EGFR signaling. Here, signals originating at the PM can
be prolonged – in order to achieve a productive signaling
response – and/or diversified – by assembling specific sig-
naling complexes (reviewed in Villasenor et al., 2016).
Furthermore, the endosome fusion and fission machin-
ery tightly controls EGFR signaling by keeping the num-
ber of EGFR clusters per endosome constant over a
wide range of EGF concentrations (Villasenor et al.,
2015), thus conferring robustness to the system. Varying
the number of EGFR clusters per endosome through
alteration of the endosome fission/fusion rate critically
impacts the EGFR signaling output, for example, prolif-
eration vs. differentiation (Villasenor et al., 2015).
A novel regulatory mechanism occurring at the EEs
has been recently described, which is able to sense the
amount of EGFRs trafficking toward the endosomes
and to induce de novo receptor biosynthesis and exocy-
tosis, in order to preserve EGFR levels at the PM
(Scharaw et al., 2016). When cells are continuously
stimulated with high EGF doses, the transcription fac-
tor RNF11 translocates from the EEs to the nucleus
where it induces transcription of genes required for
EGFR transport to the PM (Scharaw et al., 2016).
How RNF11 senses the amount of internalized EGFR
at the EEs remains an open question.
2.2. EGFR cancer mutants divert from the normal
trafficking itinerary
EGFR signaling is frequently altered in several human
cancers due to EGFR gene amplification and/or pro-
tein overexpression, mutations or in-frame deletions
(Roskoski, 2014). The most frequent mutations in
glioblastoma and lung cancer are illustrated in
Fig. 1B; this figure also includes mutations found
in colorectal cancers that are resistant to antibody-
mediated EGFR blockade]. These genetic lesions often
occur concomitantly with increased EGFR ligand pro-
duction due to autocrine or paracrine loops (Wilson
et al., 2009, 2012). In many cases, EGFR genetic alter-
ations determine abnormal EGFR trafficking, which
contributes to increased signaling and tumor develop-
ment. For instance, the increase in EGFR density at
the PM due to EGFR amplification/overexpression
was shown to stimulate receptor homo- and
heterodimerization leading to kinase activation (Chung
et al., 2010; Sawano et al., 2002; Wiley, 1988; Wilson
et al., 2009). In particular, heterodimers with the
ligand-orphan receptor ErbB2 are constitutively active,
evade receptor ubiquitination and degradation, and
are mostly recycled back to the PM, thereby producing
sustained signaling and cell proliferation (Mellman
and Yarden, 2013; Schneider and Yarden, 2016). In
agreement, saturation of the endocytic and/or the
ubiquitination machinery has been proposed as a
mechanism underlying sustained signaling in EGFR-
overexpressing cancer cells (Capuani et al., 2015;
French et al., 1994; Wiley, 1988).
Oncogenic EGFR mutations and large genetic rear-
rangements (as observed in glioblastoma, brain, lung,
breast, and ovarian cancers) often cause altered recep-
tor endocytosis, which contributes to increased signal-
ing properties (Yarden and Pines, 2012). In some
cases, mutations directly disrupt the recruitment site of
the E3 ligase, Cbl, in the intracellular domain of the
receptor (i.e., EGFRvIV and EGFRvV mutants),
thereby affecting receptor ubiquitination and lysoso-
mal degradation (Roskoski, 2014). In other instances,
mutations are located in the extracellular domain (i.e.,
EGFRvIII), leading to ligand-independent receptor
activation (Grandal et al., 2007; Han et al., 2006; Sch-
midt et al., 2003). Unexpectedly, these mutations also
caused hypophosphorylation of the intracellular tyro-
sine residue 1045, the direct Cbl-binding site, via an
unknown mechanism. In this way, receptor ubiquitina-
tion and turnover are affected, resulting in sustained
signaling (Grandal et al., 2007; Han et al., 2006; Sch-
midt et al., 2003). Somatic EGFR activating mutations
have been detected in ~ 15–20% of NSCLC patients
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(Yun et al., 2007). One of the most frequent muta-
tions, L858R, despite having a more highly phosphory-
lated Cbl-binding site than the wild-type receptor, is
impaired in Cbl recruitment and receptor ubiquitina-
tion, again affecting trafficking toward the lysosome
and receptor degradation, with consequent signal
upregulation (Kon et al., 2014; Shtiegman et al.,
2007). Increased heterodimerization of this mutant
with ErbB2 has been proposed to cause this behavior
(Kon et al., 2014).
Finally, it is important to stress that besides onco-
genic alterations, inappropriate activation of the
EGFR in cancer can originate from derailed receptor
endocytosis and trafficking (Mellman and Yarden,
2013). This is achieved by two mechanisms: either
mutated RTKs hijack the endocytic apparatus, which,
in turn, fosters their signaling properties, or altered
endocytic/trafficking genes potentiate the duration and
the amplitude of the signal (Sigismund et al., 2012).
Indeed, alterations in the balance between receptor
recycling and degradation have been found in several
aggressive cancers (Belle et al., 2015; Boulay et al.,
2016). This latter mechanism largely relies on the over-
expression and amplification of genes that are involved
in RTKs endocytosis and recycling, including several
GTPases belonging to the Rab family which control
vesicular trafficking (Caswell et al., 2007; Cheng et al.,
2004; Frittoli et al., 2014; Kajiho et al., 2016; Wheeler
et al., 2015). Increased expression of endocytic/recy-
cling molecules prolongs propagation of the signal
and/or re-locates RTKs and adhesive receptors at
specific membrane sites, mainly involved in cancer cell
invasion (Caswell et al., 2008; Eppinga et al., 2012;
also reviewed in Lanzetti and Di Fiore, 2017; Mellman
and Yarden, 2013; Mills et al., 2009; Mosesson et al.,
2008; Sigismund et al., 2012). Among these molecules,
copy number gain and overexpression of the 50-inositol
lipid phosphatase synaptojanin 2 (SYNJ2) in breast
cancer provides a paradigmatic example of sustained
EGFR activation by altered trafficking pathways. Ele-
vation of SYNJ2 promotes EGFR recycling at lamel-
lipodia, stimulating cell motility and the formation of
invadopodia (Ben-Chetrit et al., 2015).
3. Noncanonical kinase-dependent and
kinase-independent EGFR functions
In this section, we will discuss both kinase-dependent
and kinase-independent functions of the EGFR that
have recently emerged and that diverge from the
canonical EGFR signaling pathway. For what con-
cerns kinase-independent roles, their existence has been
known for many years. Indeed, while EGFR-knockout
mice are mid-gestation or perinatal lethal (depending
on the genetic background), due to gross developmen-
tal defects (Miettinen et al., 1995; Sibilia and Wagner,
1995; Threadgill et al., 1995), kinase-dead EGFR-
knock-in mice are viable, displaying only mild defects
in the eye and skin (Luetteke et al., 1994). In addition,
the EGFR is able to promote cell survival pathways
through both kinase-dependent and kinase-indepen-
dent mechanisms (Ewald et al., 2003; Tan et al.,
2016a). These EGFR kinase-independent functions
could result from the heterodimerization of the EGFR
with other ErbB family members or could be mediated
by kinases that crosstalk with the EGFR pathway
(e.g., Src or p38-MAPK, see Section 3.2). Moreover,
inactivation of phosphatases (e.g., PTP1B, see Sections
3.1 and 3.2) might contribute to activation of EGFR
signaling. More work is needed to address whether
these mechanisms are at play in living cells and
whether they are mutually exclusive or coexisting in
the regulation of EGFR function.
3.1. ER contact sites regulate EGFR signaling at
different steps of the endocytic pathway
Communication between organelles is critical for sev-
eral fundamental cellular processes, including organelle
positioning and function, organelle fission, lipid trans-
port, and Ca2+ signaling (van Bergeijk et al., 2016;
Phillips and Voeltz, 2016; Saheki and De Camilli,
2017). Communication occurs through so-called con-
tact sites: regions of juxtaposition (≤ 20 nm) between
two heterologous membranes, tethered by in trans pro-
tein–protein interactions (Eisenberg-Bord et al., 2016;
Phillips and Voeltz, 2016). In particular, the ER, due
to its tubular organization that extends all over the
cell, has been shown to make contact and to exchange
materials with all of the other cellular organelles (Phil-
lips and Voeltz, 2016).
ER contact sites have a critical role in controlling
EGFR signaling and trafficking at multiple steps. Dur-
ing the initial phase of endocytosis, high doses of EGF
are able to induce tubulation of cortical ER and the
formation of ER contact sites with the PM, at regions
where the EGFR is internalizing via NCE (Caldieri
et al., 2017; Fig. 2). The formation of these contact
sites is critical to induce local Ca2+ signaling at ER–
PM interface, which is in turn required for the fission
of NCE tubular intermediates and, thus, for comple-
tion of the internalization process (Caldieri et al.,
2017). This mechanism ultimately leads to EGFR
endocytosis via NCE, receptor degradation, and signal
termination (Caldieri et al., 2017; Sigismund et al.,
2008). Polarized Ca2+ waves might also be critical in
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specifying the final EGFR-NCE signaling output,
given the role of Ca2+ in growth factor-induced cell
migration (Tsai et al., 2014), an issue that requires fur-
ther investigation.
All along the endocytic route, the ER makes con-
tact with the endosomes and these contact sites
increase as endosomes traffic and mature (Friedman
et al., 2013). ER–endosomal contact sites are critical
in defining the timing and position of endosome fis-
sion during cargo sorting (Rowland et al., 2014), but
they also have a direct role in the regulation of
EGFR signaling. Indeed, a major RTK phosphatase,
Fig. 2. Active and inactive EGFR-related functions. This picture schematizes some noncanonical EGFR functions. From left to right: EGFR
stimulated with high EGF doses (active EGFR) is phosphorylated (P) and ubiquitinated (Ub) and undergoes both clathrin-mediated
endocytosis (not depicted) and nonclathrin-dependent endocytosis (NCE), the latter dependent on the formation of RTN3-mediated ER–PM
contact sites. This is accompanied by calcium release in the proximity of contact sites, which likely controls fission of the tubular
invagination. It is still unclear whether RTN3 is the tethering factor between the ER and the PM (as depicted), or it is just involved the
tubulation of cortical ER, but not directly engaged at contact sites. EGFR ligand stimulation elicits the classical signaling cascade based on
the recruitment of PI3K (made of its p85 regulatory subunit and p110 catalytic subunit) that catalyzes the formation of PIP3s. PIP3s bind to
the PH domain of AKT and of phosphoinositide-dependent kinase-1, PDK1. PDK1 phosphorylates AKT on Thr308, while mammalian target
of rapamycin complex 2, mTORC2 (not depicted here), is responsible for phosphorylation on Ser 473, leading to full AKT activation. Active
AKT inhibits autophagy and blocks GLUT1 endocytosis. This latter function leads to higher levels of GLUT1 at the plasma membrane,
increasing the uptake of glucose. In addition, ligand-independent direct interaction of EGFR (inactive EGFR) and SGLT1 stabilizes the glucose
transporter at the cell surface promoting high glucose uptake. Ligand-unbound EGFR constitutively internalizes into early and late
endosomes where it is sequestered by LAPTM4B. Here, the inactive EGFR interacts with Rubicon causing its dissociation from Beclin-1.
Beclin-1 complex can now initiates autophagy on the ER membrane.
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PTP1B, localizes to the cytosolic face of the ER and
dephosphorylates the EGFR in trans during its traf-
ficking to the endosomes/MVBs (Eden et al., 2010;
Haj et al., 2002). Of note, PTP1B regulates constitu-
tively internalized EGFR, thereby restricting spurious
EGFR kinase activation, as well as ligand-activated
receptor that is dephosphorylated by PTP1B on the
way to the lysosome (Baumdick et al., 2015). The
formation of ER–MVB contact sites is mediated by
annexin-1 and is Ca2+ dependent (Eden et al., 2016;
Kilpatrick et al., 2017). The release of Ca2+ occurs
through the two-pore channel that is localized on the
endolysosomal membrane at ER contact sites (Kil-
patrick et al., 2017). Disrupting these contact sites
has been shown to delay PTP1B-mediated EGFR
dephosphorylation, causing delayed receptor degrada-
tion and enhanced signaling (Eden et al., 2016; Kil-
patrick et al., 2017).
3.2. Stress-induced EGFR trafficking pathways
Different stresses applied to cells have been shown to
stimulate EGFR endocytosis and trafficking in a
ligand-independent fashion. For instance, UV radia-
tion, cisplatin, inflammatory cytokines (tumor necrosis
factor a), and the antibiotic anisomycin all trigger
p38-MAPK activation, required for ligand-independent
EGFR internalization (reviewed in Tan et al., 2016a;
Tomas et al., 2014).
While the mechanism is similar for all these treat-
ments, it has been most extensively characterized in the
case of UV treatment. UV-stimulated EGFR endocyto-
sis occurs via CME and depends on the phosphorylation
of serine/threonine residues in the C-terminal receptor
tail mediated by p38-MAPK activity (Oksvold et al.,
2004; Tomas et al., 2017; Tong et al., 2014; Vergarajau-
regui et al., 2006; Zwang and Yarden, 2006). Interest-
ingly, other receptors, such as the insulin receptor,
c-MET, and the transferrin receptor, are not internalized
upon UV treatment, suggesting the existence of some
level of specificity (Zwang and Yarden, 2006). Once
internalized, EGFRs accumulate in a subpopulation of
MVBs, distinct from the EGF-induced MVB pool,
where they are entrapped into intraluminal vesicles
(ILVs) without being degraded (Oksvold et al., 2002;
Tomas et al., 2015). The process is reversible as, upon
p38-MAPK inhibition, ILV-localized EGFRs can be
recovered to the limiting MVB membrane from which
they are recycled back to the PM (Tomas et al., 2015).
EGFR also responds to hypoxia, which, on the one
hand, upregulates the transcription of the EGFR gene,
providing a mechanism for EGFR overexpression in
the absence of genetic alterations (Franovic et al.,
2007); on the other hand, it triggers EGFR Src-depen-
dent, caveolae-dependent endocytosis (Shen et al.,
2013). At endosomes, EGFRs bind and phosphorylate
the endosomal membrane-associated protein, arg-
onaute 2, a molecule involved in micro-RNA
(miRNA) maturation, causing inhibition of the matu-
ration of tumor suppressor miRNAs, thus promoting
cancer cell survival (Shen et al., 2013). A similar mech-
anism of EGFR internalization and endosomal accu-
mulation appears to be at work also in the case of
oxidative stress induced by H2O2 (Filosto et al., 2011;
Khan et al., 2006; Ravid et al., 2002). In this case, the
generation of reactive oxygen species inactivates redox-
sensitive, cysteine-based, tyrosine phosphatases, includ-
ing PTP1B, causing the activation of Src and, possibly,
of the EGFR itself (Denu and Tanner, 1998; Lee
et al., 1998). Src-dependent caveolae-mediated EGFR
endocytosis is also activated by ionizing radiation.
Importantly, mechanisms of resistance to ionizing radi-
ation depend on the EGFR (Dittmann et al., 2008).
Indeed, this treatment increases EGFR expression,
induces Src activation and caveolae-mediated EGFR
endocytosis. Phosphorylation of threonine 654 in the
EGFR juxtamembrane region by PKCe negatively reg-
ulates Cbl-dependent ubiquitination and promotes
EGFR nuclear translocation, leading to enhanced
DNA repair and cell survival (Dittmann et al., 2008;
Wanner et al., 2008). In agreement, EGFR nuclear
localization has been associated with radiation resis-
tance and poor clinical outcome (Tan et al., 2016a;
Tomas et al., 2014).
In conclusion, it is emerging that multiple mecha-
nisms of ligand-independent trafficking are activated
under stress conditions and that these mechanisms can
promote cancer cell survival. However, more work is
needed to molecularly dissect these pathways, in order
to clarify how they are regulated, how they interplay
with the canonical EGFR pathway, and whether they
can be hijacked to prevent resistance to anti-EGFR
therapies.
3.3. Role of EGFR in autophagy
Autophagy is critical in maintaining cellular homeosta-
sis and is finely regulated under physiological condi-
tions to allow cells to rapidly respond to
environmental changes. It is deregulated in different
pathologies, including neurodegenerative diseases,
aging, and cancer, and is one of the major mechanisms
promoting resistance to cancer therapies (for recent
reviews see, for instance Galluzzi et al., 2015, 2017;
Goldsmith et al., 2014; Menzies et al., 2015; Rubin-
sztein et al., 2012).
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The EGFR is a crucial regulator of autophagy. In
nutrient-rich growth conditions, ligand-activated
EGFR has a dual activity: on the one hand, it stimu-
lates cell proliferation; on the other, it inhibits autop-
hagy. Inhibition of autophagy is achieved: (a) directly,
through the phosphorylation and consequent inhibi-
tion of Beclin-1, a core subunit of the VPS34/au-
tophagy initiation complex (Wei et al., 2013), and (b)
indirectly, through the activation of AKT. In turn,
AKT activates the mechanistic target of the rapamycin
complex 1 (mTORC1) pathway, which ultimately inhi-
bits autophagy (Tan et al., 2016a).
In contrast, under serum-starved conditions, inactive
EGFR is emerging as a promoter of autophagy. In this
case, ligand-unbound receptors, which constitutively
traffic toward the endosomes, are sequestered by the
lysosomal-associated protein transmembrane 4 beta
(LAPTM4B), localized in a subpopulation of early and
late endosomes. The increased EGFR endosomal pool
interacts with the autophagy inhibitor, Rubicon, caus-
ing its dissociation from Beclin-1, leading to Beclin-1
activation and autophagy initiation (Tan et al., 2015a,b;
Fig. 2). This function is maintained by the kinase-dead
EGFR mutant, confirming that it is indeed independent
of kinase activation (Tan et al., 2015b). The loss of
EGFR generates cells defective in autophagy initiation,
at variance with the loss of other RTKs, including c-
MET, PDGFR, and FGFR2 (Tan et al., 2015b), sug-
gesting that this is an EGFR-specific function.
Autophagy initiation seems to occur at ER–endo-
some contact sites. In particular, to initiate autophagy,
autophagy-related gene 14 on the ER surface has to
interact with PIPKIci5 kinase (PIPKIci5K), an enzyme
localized on endosomal membranes in complex with
inactive EGFR and LAPTM4B. This binding stimu-
lates phosphatidylinositol 4,5-bisphosphate (PIP2) pro-
duction by PIPKIci5 and autophagy (Tan et al.,
2016b). Thus, ER contact sites seem to provide a plat-
form for autophagic complex assembly.
Interestingly, the ER-resident protein RTN3, which
is required for the establishment of ER–PM contact
sites needed for EGFR endocytosis via NCE (Caldieri
et al., 2017), has also been implicated in ER turnover
by selective autophagy (Grumati et al., 2017). A
specific RTN3 isoform, which possesses multiple LC3-
interacting regions, has been found to exert this
function (Grumati et al., 2017). Whether these two
functions of RTN3 are related, and how they are inte-
grated within the cell, is not yet known; however, they
might unveil connections between ligand-dependent
and ligand-independent EGFR trafficking pathways.
Activation of autophagy has been found to promote
resistance and survival of cancer cells treated with
EGFR kinase inhibitors (Tan et al., 2016b). The mech-
anism seems to resemble the one induced by
LAPTM4B in the physiological context. Indeed, these
compounds promote endosomal accumulation of the
EGFR, enhancing its association with Rubicon and
favoring the dissociation of Rubicon/Beclin-1 complex,
thereby initiating the autophagic flux (Tan et al.,
2015a). It is possible that other stresses causing EGFR
endosomal accumulation (discussed in Section 3.2)
might also activate autophagy as a part of their sur-
vival response, a scenario that deserves further investi-
gation.
3.4. Mitochondrial functions of EGFR
The EGFR is usually considered to act at the PM and
on vesicles mainly belonging to the endosomal com-
partment. However, it also localizes to the nucleus and
mitochondria. Translocation of full-length EGFR into
the nucleus has long been documented and the func-
tions it has at this location have been extensively
investigated; we therefore refer the readers to detailed
reviews (Brand et al., 2011; Han and Lo, 2012). Differ-
ently, the role of EGFR in mitochondria is more elu-
sive and has been connected with antiapoptotic and
metabolic functions.
In NSCLC cells, high levels of EGFR expression
have been detected in the mitochondria (Che et al.,
2015). In these cells, artificially mitochondria-targeted
EGFR redistributes these organelles to lamellipodia,
increasing cell motility, possibly through the localized
increase in energy (Che et al., 2015). In addition,
translocation of wild-type EGFR and of the EGFR-
vIII mutant into mitochondria has also been observed
in cells treated with kinase inhibitors, or following
proapoptotic stimuli (Cao et al., 2011). This transloca-
tion correlates with resistance to apoptosis and
decreased sensitivity to EGFR inhibition (Cao et al.,
2011). The latter function might be related to the abil-
ity of both wild-type EGFR and EGFRvIII to consti-
tutively bind to p53-upregulated modulator of
apoptosis (PUMA), a proapoptotic member of the
Bcl-2 family of proteins primarily located in the mito-
chondria (Zhu et al., 2010).
In breast cancer cells, translocation of EGFR to
mitochondria has been shown to occur upon EGF
stimulation resulting in phosphorylation of the cyto-
chrome c oxidase subunit II (Boerner et al., 2004;
Demory et al., 2009). The biological outcome of this
modification is not clear. However, this event requires
phosphorylation of the EGFR on tyrosine 845 by Src,
which also undergoes mitochondrial translocation with
similar kinetics to that of the EGFR (Demory et al.,
11Molecular Oncology 12 (2018) 3–20 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
S. Sigismund et al. Novel functions of the EGFR in cancer
2009). Of note, EGF stimulation also induces palmi-
toylation of mitochondrial EGFR, which, in turn,
favors fusion of mitochondria (Bollu et al., 2014).
EGFR, independently of its kinase activity, interacts
with the fatty acid synthase, stimulating de novo syn-
thesis of palmitate (Bollu et al., 2014). This finding
points to the involvement of the EGFR in the regula-
tion of cell metabolism and supports the existence of a
signaling-metabolic wiring that plays a critical role in
cancer.
3.5. Role of EGFR in cancer cell metabolism
Oncogenic signaling pathways induce metabolic repro-
gramming in cancer cells supporting tumor growth
(Cairns et al., 2011). In this context, EGFR signaling
has been involved in the regulation of several meta-
bolic processes that are critical for cancer cell prolifer-
ation: from the biosynthesis of fatty acids and
pyrimidines, to glucose catabolism (Guo et al., 2009;
Makinoshima et al., 2014). The EGFR promotes these
metabolic pathways both directly by phosphorylating
rate-limiting enzymes (Lim et al., 2016; Zhang et al.,
2017), or indirectly through activation of the MYC
transcription factor and of the AKT signaling cascade
(Babic et al., 2013; Guo et al., 2009; Makinoshima
et al., 2014, 2015, and reviewed in DeBerardinis and
Chandel, 2016; Masui et al., 2014).
In glioblastoma multiforme, oncogenic EGFR sig-
naling by EGFRvIII stimulates the PI3K/AKT-depen-
dent nuclear translocation of sterol regulatory element-
binding protein 1 (SREBP-1) and the expression of the
low-density lipoprotein receptor (LDLR). Increased
LDLR, in turn, allows for the uptake of cholesterol
bypassing negative feedback regulation (Guo et al.,
2009). This represents a point of metabolic vulnerabil-
ity as these cells depend on cholesterol uptake and are
highly sensitive to inhibitors of fatty acid and choles-
terol biosynthesis (Guo et al., 2011).
Furthermore, the EGFR has been recently found to
directly phosphorylate and, thereby, stabilize stearoyl-
CoA desaturase-1 (SCD1), resulting in the upregula-
tion of monounsaturated fatty acid production (Zhang
et al., 2017). Notably, phosphorylation of SDC1 corre-
lates with poor prognosis of glioblastoma multiforme
(Zhang et al., 2017), suggesting that it might have a
causative role in these tumors.
One of the best-studied metabolic drifts in cancer
cells is the elevation of glycolysis in the presence of
oxygen: the Warburg effect. Cancer cells are generally
characterized by the avid uptake of glucose, which
occurs through increased expression and membrane
localization of glucose transporters, mainly GLUT1
and GLUT3 (Barron et al., 2016). Intracellular glucose
is metabolized to pyruvate that, in cancer cells, is pref-
erentially converted into lactate (Cairns et al., 2011).
The EGFR has been shown to foster aerobic glycol-
ysis through several, both kinase-dependent and
kinase-independent, mechanisms (Fig. 2). Physical
association of EGFR with SGLT1 stabilizes the
sodium-glucose cotransporter at the cell surface
increasing the glucose influx (Weihua et al., 2008).
This kinase-independent function provides survival
advantages to cells, helping them escape autophagic
cell death when grown in the presence of low glucose
concentrations (Weihua et al., 2008).
In response to EGF stimulation, the EGFR controls
expression of hexokinase (HK1) and phosphorylation
of the pyruvate kinase M2 (PKM2), two glycolytic
enzymes that catalyze key steps in the pathway, thus
increasing aerobic glycolysis of breast cancer cells
(Lim et al., 2016). One relevant ‘side effect’ of
increased aerobic glycolysis is the production of high
levels of lactate that, in these tumors, inhibits the cyto-
toxic activity of T cells, supporting their immune
escape (Lim et al., 2016).
In lung adenocarcinoma cells bearing oncogenic
EGFR mutations, deregulated signaling has been
shown to stabilize GLUT1 at the cell surface through
the activation of the PI3K/AKT/mTOR pathway
(Makinoshima et al., 2015). Indeed, activation of AKT
in response to cytokine stimulation has long been
known to inhibit endocytosis of GLUT1 in lymphoid
cells (Wieman et al., 2007; Wofford et al., 2008).
Recent findings showing that AKT phosphorylates
and inhibits thioredoxin-interacting protein (TXNIP),
the endocytic adaptor responsible for CME of GLUT1
(Hong et al., 2016; Waldhart et al., 2017), suggest that
this might be the mechanism at work.
Of note, inhibition of the PI3K/AKT/mTOR path-
way in lung cancer cells harboring EGFR mutations
affects the glycolytic flux impairing their viability
(Makinoshima et al., 2015). In line with these findings,
combined inhibition of EGFR and glycolysis has been
shown to synergistically suppress proliferation of tri-
ple-negative breast cancer cells (Lim et al., 2016), fur-
ther supporting the relevance of EGFR signaling in
cancer cell metabolism.
3.6. Membrane trafficking influences the efficacy
of EGFR-targeted therapies
Given its critical role in cancer, several EGFR-targeted
therapies have been developed, including monoclonal
humanized antibodies (mAbs) directed against the
receptor extracellular domain, as well selective small-
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molecule inhibitors targeting the tyrosine kinase
domain. Small-molecule EGFR inhibitors (e.g., gefi-
tinib, erlotinib, and afatinib) have been approved for
lung cancer treatment as a first-line therapy in those
cases where EGFR mutations have been confirmed
(Cohen et al., 2005; Hirsch et al., 2013; Thatcher
et al., 2005). Interestingly, in addition to kinase inhibi-
tion, gefitinib was shown to increase the formation of
inactive EGFR dimers through some form of commu-
nication between the kinase domain and the extracellu-
lar dimerization domain, suggesting the possibility that
gefitinib-induced dimers could be more rapidly endocy-
tosed and degraded (Arteaga et al., 1997; Gan et al.,
2007), an issue that warrants further studies.
Cetuximab and panitumumab are the most widely
employed EGFR-neutralizing monoclonal antibodies,
used for the treatment of head and neck cancer and
metastatic colon cancer (Licitra et al., 2013; Peeters
et al., 2015; Pierotti et al., 2010). Mechanistically,
these compounds act by preventing ligand binding,
thereby inhibiting receptor activation and downstream
signaling (Bou-Assaly and Mukherji, 2010; Dubois
and Cohen, 2009; Vincenzi et al., 2008). They also
favor EGFR dimerization, which, in turn, causes inter-
nalization of antibody-bound dimers. These complexes
are internalized at a lower rate and are more efficiently
recycled to the PM compared with EGF-bound dimers
(Jaramillo et al., 2006). The combined use of anti-
EGFR antibodies directed against nonoverlapping
antigens appears to be a more efficient strategy than
the use of single antibodies, as it increases EGFR
endocytosis and degradation (Ferraro et al., 2013;
Friedman et al., 2005; Pedersen et al., 2010), raising
the possibility of improving antitumor efficacy through
the regulation of EGFR trafficking.
Currently, however, EGFR antibody-based thera-
pies, as well as small-molecule inhibitors, have been
shown to exert a limited response and to frequently
evoke resistance in patients due to (a) secondary muta-
tions within the EGFR itself (e.g., T790M in NSCLC,
and mutations found in the extracellular domain of
cetuximab-resistant colorectal cancers, Fig. 1B), (b)
alterations in other kinases (e.g., c-MET, PIK3CA,
BRAF, MAPK1), or (c) the emergence of feedback
regulatory loops and mechanisms that overcome
EGFR kinase inhibition (reviewed in Mancini and
Yarden, 2016). In the latter case, the effect of therapies
might be dampened by the activation of ligand-inde-
pendent EGFR trafficking pathways and functions,
such as increased autophagy and elevated aerobic gly-
colysis (discussed in Sections 3.3 and 3.5). In addition,
mechanisms that likely contribute to the emergence of
drug resistance include also (a) relocalization of the
EGFR to the nucleus following ionizing irradiation to
promote DNA repair (Liccardi et al., 2011; Szumiel,
2006) and (b) translocation to mitochondria upon
kinase inhibitor treatment to exert antiapoptotic effects
(Cao et al., 2011; detailed in Section 3.4).
Concluding remarks
The EGFR has long been considered the prototype of all
RTKs. Indeed, most of the knowledge accumulated on
signal transduction cascades in general and on the mech-
anisms underlying receptor endocytosis, recycling, and
degradation has derived from studies focused on the
EGFR. Nevertheless, novel unexpected functions of this
receptor continue to emerge, some of which are linked to
previously unrecognized subcellular localizations. Thus,
despite the large body of knowledge already accumu-
lated, this receptor still holds a number of surprises.
An emerging aspect that could be exploited for can-
cer treatment is the study of how membrane trafficking
can influence the outcome of EGFR-targeted thera-
pies. Findings in this area could increase efficacy and
overcome or delay the occurrence of resistance to
treatments, an adverse event that invariably occurs in
the patient population. Recently, in an attempt to
overcome tumor resistance, simultaneous targeting of
driver mutations and basic cellular processes has been
proposed as a promising therapeutic perspective
(Nagel et al., 2016). In this framework, endocytosis/re-
cycling, autophagy, and metabolism might represent
targets for the development of inhibitory tools to be
tested in combination with EGFR inhibitors (Mellman
and Yarden, 2013). A similar approach is currently
being undertaken in tumors where the oncogenic
EGFR signaling promotes metabolic reprogramming
with promising results.
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